Esuberaprost

Drug Profile

Esuberaprost

Alternative Names: 314d; APS-314d; Beraprost Sodium 314d Modified Release; Beraprost-314d; BPS-314d-MR; L-314d-QID

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Toray
  • Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pulmonary arterial hypertension

Most Recent Events

  • 27 Jul 2017 United Therapeutics completes enrolment in a phase-III clinical trial in Pulmonary arterial hypertension in USA prior to July 2017 (PO) (NCT01908699; 9220286)
  • 30 May 2013 Phase-III clinical trials in Pulmonary arterial hypertension in USA (PO) (NCT01908699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top